Brief: Xeris Biopharma Q4 Product Revenue USD 83.43 Million Versus. Ibes Estimate USD 82.3 Million
02/03/2026 14:01
March 2 (Reuters) - Xeris Biopharma Holdings Inc XERS.O: XERIS BIOPHARMA Q4 OPERATING INCOME USD 16.773 MILLION XERIS BIOPHARMA Q4 PRODUCT REVENUE USD 83.43 MILLION VERSUS. IBES ESTIMATE USD 82.3 MILLION XERIS BIOPHARMA Q4 EPS USD 0.06 XERIS BIOPHARMA Q4 NET INCOME USD 11.081 MILLION EXPECTS 2026 REVENUE BETWEEN $375 MILLION AND $390 MILLION FY2026 REVENUE VIEW $368.1 MILLION -- LSEG IBES DATA Source text: ID:nBw6df2Bwa Further company coverage: XERS.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Xeris Biopharma Holdings
See all newsBrief: Xeris Biopharma Announces Private Exchange Of Convertible Notes
Xeris Biopharma Q1 product revenue jumps 43%, beats estimates
Brief: Xeris Biopharma Q4 Product Revenue USD 83.43 Million Versus. Ibes Estimate USD 82.3 Million
Xeris Biopharma Q4 product revenue beats analyst expectations, driven by higher patient demand
Brief: Xeris Biopharma Subsidiaries File Recorlev Patent Infringement Lawsuit